Non-small cell lung cancer clinical trials

Explore recruiting non-small cell lung cancer clinical trials.

Recruiting non-small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non-small cell lung cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Poland, Spain, Portugal, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)

Netherlands, Germany, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Preoperative amivantamab or amivantamab and carboplatin/pemetrexed treatment in patients with resectable non-small-cell lung cancer harboring oncogenic EGFR mutations (NEOpredict-EGFR)

Germany, Belgium, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies

Italy, Bulgaria, Poland, Romania, France, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Italy, Romania, Poland, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Non-small cell lung cancer trials by city

Non-small cell lung cancer in Toronto Non-small cell lung cancer in Vancouver Non-small cell lung cancer in Montreal Non-small cell lung cancer in Calgary Non-small cell lung cancer in Edmonton Non-small cell lung cancer in Ottawa Non-small cell lung cancer in Winnipeg Non-small cell lung cancer in Quebec City Non-small cell lung cancer in Hamilton Non-small cell lung cancer in Kitchener Non-small cell lung cancer in London Non-small cell lung cancer in Halifax Non-small cell lung cancer in New York Non-small cell lung cancer in Los Angeles Non-small cell lung cancer in Chicago Non-small cell lung cancer in Houston

Other conditions

Hidradenitis suppurativa Rosacea Alopecia areata Endometriosis Uterine fibroids Menopause Infertility Erectile dysfunction Enlarged prostate (BPH) Breast cancer Prostate cancer Lung cancer Colorectal cancer Pancreatic cancer Ovarian cancer Melanoma Leukemia Lymphoma Multiple myeloma Bladder cancer Kidney cancer Liver cancer Glioblastoma Head and neck cancer